Determination of dabigatran in human plasma samples.

Abstract

The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous thromboembolism using fixed doses without the need for adjustment according to laboratory results. Dabigatran is eliminated from the circulation by ∼80% through the kidneys. However, the in vitro anticoagulant effect of dabigatran may be necessary to determine in special patient populations such as in the elderly, for renal impairment, before operations, bleeding or thrombotic episodes, and to monitor self-compliance. Several clotting and thrombin-specific chromogenic substrate assays are available to analyze the biological activity of dabigatran. All of them are prolonged in the presence of dabigatran. This article reports the effects of dabigatran on clinical routine assays and the potential usefulness for determination in special risk groups of patients when overdose or lack of compliance are suspected.

• Authors: Job Harenberg, Christina Giese, Svetlana Marx, Roland Krämer
• Journal: Seminars in thrombosis and hemostasis (Semin Thromb Hemost) Vol. 38 Issue 1 Pg. 16-22 (Feb 2012) ISSN: 1098-9064 [Electronic] United States
• PMID: 22314599 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chemical References

• Anticoagulants
• Benzimidazoles
• beta-Alanine
• Dabigatran

Topics

• Anticoagulants (blood, therapeutic use)
• Benzimidazoles (blood, therapeutic use)
• Dabigatran
• Humans
• Thromboembolism (prevention & control)
• beta-Alanine (analogs & derivatives, blood, therapeutic use)